Three Analysts Initiate Coverage On This Newly Listed Precision Oncology Firm

Wedbush initiated coverage of Tango Therapeutics Inc TNGX with an Outperform rating and a $12 price target.
Analyst Robert Driscoll believes Tango's unique synthetic lethality approach is differentiated.
Furthermore, he expects Tango to leverage this comprehensive platform to drive the discovery and development of many programs that lead to significant value creation.
Goldman Sachs initiated coverage of Tango Therapeutics with a Buy rating and a $17 price target.
Analyst Chris Shibutani believes Tango is "strongly positioned" as a precision oncology company.
The Company's proprietary drug discovery platform utilizes a synthetic lethality-based approach that addresses the "vast, largely untapped realm" of cancers driven by tumor suppressor gene loss, Shibutani tells investors in a research note.
Guggenheim initiated coverage of Tango Therapeutics with a Buy rating and a $16 price target.
Tango started trading on NASDAQ a couple of weeks back.
Its lead program TNG908 is a protein arginine methyl transferase 5 (PRMT5) inhibitor that is synthetic lethal with MTAP deletion.
IND submission for human trials is expected in Q4 of 2021.
Price Action: TNGX shares are up 15.2% at $14.89 during the market session on the last check Tuesday.